Does Massachusetts Medicaid cover Mounjaro?

Quick answer · Type 2 Diabetes

Massachusetts Medicaid covers Mounjaro for type 2 diabetes with prior authorization on Medicaid.

The card and program names below are mapped to Massachusetts Medicaid in our records. Coverage depends on the reason for treatment and the requirements in the policy.

Policy last verified June 4, 2026. Source: policy-348.html. How we verify this data.

Card and program names on file in Massachusetts

Select a name to read the Massachusetts Medicaid policy for Mounjaro. These are names we recognize, including older names and spelling variants; this is not a list of plans currently accepting members.

Don't see your card name? Check your card or call the pharmacy-benefit number on your card. If you also have Medicare, confirm which plan handles this prescription.

Mounjaro for Type 2 Diabetes

Medicaid

Covered (preferred drug)

What you need to qualify

  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Initial approval for type 2 diabetes

All of:

  • Appropriate diagnosis of type 2 diabetes
  • Baseline A1C dated within 90 days prior to initiation
  • Requested agent will not be used in combination with another GLP-1 receptor agonist
  • If requested quantity exceeds quantity limits, clinical rationale provided

SmartPA for type 2 diabetes (no PA request needed)

All of:

  • Claims within quantity limit
  • Member has history of medical claims for type 2 diabetes mellitus OR history of medical claims for prediabetes with history of paid claims for at least 84 days of GLP-1/GIP/GLP-1 agonist therapy within the last 120-day period

Documentation to bring

  • Appropriate diagnosis of type 2 diabetes
  • Baseline A1C lab result dated within 90 days prior to initiation
  • Attestation that requested agent will not be used in combination with another GLP-1 receptor agonist
  • If quantity exceeds limits: clinical rationale why dose cannot be consolidated or for exceeding FDA-approved dosing
  • For recertification: current A1C dated within last 90 days
  • For recertification: evidence of A1C reduction, A1C ≤ 7%, or treatment plan for A1C escalation

Quantity limits

  • all strengths — 1 carton of 4 prefilled pens per 28-day supply

Approval and renewal

  • To renew, the plan looks for improvement in A1C and Current A1C within last 90 days required. Must show: reduction in A1C since initiation, OR A1C ≤ 7% (dated within last 90 days), OR treatment plan addressing escalation of therapy for A1C reduction.

Not covered when

  • Combination use with another GLP-1 receptor agonist is prohibited unless transitioning (with discontinuation of prior GLP-1)

Policy note: Mounjaro is a Preferred Drug (PD) in the MassHealth formulary for type 2 diabetes (listed as GIP/GLP-1 Agonist). No step therapy through lower-potency GLP-1s is required for initial T2DM approval. Mounjaro 15 mg (maximum dose) is itself a step-therapy prerequisite for other agents (e.g., Bydureon Bcise, Rybelsus, Soliqua, Xultophy) requiring prior failure of 'high-potency GLP-1s'. Prediabetes indication also covered under same section with metformin step-therapy requirements. SmartPA pathway applies.

verified June 4, 2026 · source: policy-348.html

Full Massachusetts Medicaid coverage page for Mounjaro

Other medications under Massachusetts Medicaid

All insurance plans · All medications

This page summarizes written Medicaid policies on file. It is not a guarantee of coverage or medical advice. Confirm your current benefits and prior-authorization requirements with your plan.